Equity-based Compensation

6 Months Ended

Jun. 28, 2019

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Equity-based Compensation

10. Equity-based Compensation

During the 2019 second quarter and year-to-date period, the Company granted restricted stock totaling 203,400 and 418,726 shares, respectively, which were funded out of treasury stock. During the 2018 second quarter and year-to-date period, the Company granted restricted stock totaling 214,054 and 475,550 shares, respectively, which were funded out of treasury stock.

Director Board fees are paid exclusively in deferred stock units. All of the 215,326 shares granted during 2019 first quarter represented restricted stock units that were granted to Board members. The shares vest in four equal quarterly increments. The Company is expensing these grants ratably during the quarter in which they vest. Grants of similar units to the Board members totaled 118,154 and 159,175 in the 2018 second quarter and year-to-date period.      

No performance awards were granted during the 2019 first or second quarters. Of the 261,496 shares granted in the 2018 first quarter, 216,600 shares represented performance grants with a market condition that were granted to senior management on March 20, 2018. Under these grant agreements, the Company’s stock price must increase 50% to $12.27 for a 30-day period within a three-year period from the date of grant for 50% of the grants to vest. The Company’s stock price must increase 100% to $16.36 for a 30-day period within a three-year period from the date of grant for the remaining 50% of the grants to vest.

For these performance grants, the price on the date of grant was $8.18 per share, the expected volatility was 34.5%, the expected dividend yield is zero, and the risk-free rate of return was 2.47%. Given these assumptions, the

tranche of the grants that will vest with a 50% increase in the stock price have a value using a binomial model of $2.30 per share, and a derived service period of 1.26 years.  For the tranche of the grants that will vest with a 100% increase in the stock price, the value of the shares is $1.30 per share and have a derived service period of 1.85 years.  The Company is expensing these grants over the derived service period as noted for each tranche of a grant.

The remaining shares granted in the 2018 or 2019 second quarter or year-to-date periods include shares that primarily vest ratably over four years, beginning one year from the date of grant. A small number of the shares granted vest over a period of three years, with 33% of the grant vesting one year from the date of grant, and another 33% vesting each year thereafter until the grant is fully vested to the employee.

The restricted shares granted are considered outstanding, can be voted, and are eligible to receive dividends in the event any are paid. However, the restricted shares do not include a non-forfeitable right for the holder to receive dividends and none will be paid in the event the awards do not vest. Accordingly, only vested shares of outstanding restricted stock are included in the basic earnings per share calculation. The shares and share units were granted from the 2010 Equity Award Plan and the 1991 Restricted Stock plan.

No stock options were issued during the 2019 first quarter. A total of 26,500 options were granted during the 2019 second quarter on May 31, 2019.  The options have a fair value of $1.26 per share using the Black-Scholes valuation model.  The assumptions used to calculate the fair value include the price on the date of grant of $4.20 per option, an expected life of 3.7 years, expected volatility of 36.1%, an expected dividend yield of zero, and a risk free rate of 2.2%. The Company granted 13,100 stock options during the 2018 first quarter on February 20, 2018.  The options have a fair value of $1.91 per share using a Black-Scholes valuation model.  The assumptions used to calculate that fair value include the price on date of grant of $6.45 per option, an expected life of 3.7 years, expected volatility of 34.9%, an expected dividend yield of zero, and a risk free rate of 2.4%. The options vest ratably over three years, and are being expensed over that period. The options were granted from the 2010 Equity Award Plan.